NAMUH, Ginkgo Bioworks Ink Partnership To Develop Functional Oligosaccharides

RTTNews | Pred 1022 dňami
Stocktwits
NAMUH, Ginkgo Bioworks Ink Partnership To Develop Functional Oligosaccharides

(RTTNews) - Infant nutrition company NAMUH and Ginkgo Bioworks Holdings, Inc. (DNA) announced Wednesday a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those found in human breast milk.

NAMUH's mission is to create complete infant formula products substantially comparable to human breast milk, down to the molecular level.

Human Milk Oligosaccharides (HMOs) are essential fiber-like nutrients unique to human milk that provide an important energy source to beneficial gut bacteria in infants.

Despite being the third most abundant component in human milk, HMOs are currently a small component in infant formulas, if present at all.

Currently, NAMUH's proprietary technology provides for a cost-effective source of a family of HMOs via yeast fermentation.

Through this partnership, NAMUH will leverage Ginkgo's expertise in yeast strain engineering and fermentation process development to enable the production of various HMOs through yeast fermentation and work to unlock the possibility of making infant formula nutritionally robust and much closer to human breast milk.

Značky: DNA
Stocktwits
read more
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced Thursday the acquisition of microbial innovation firm AgBiome, Inc.'s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
RTTNews | Pred 573 dňami
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.
RTTNews | Pred 665 dňami
Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.
RTTNews | Pred 1199 dňami
Australian Market Halves Its Early Gains In Mid-market

Australian Market Halves Its Early Gains In Mid-market

The Australian market is halving its early gains in mid-market moves on Thursday, reversing some of the losses in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,800 level, with gains across most sectors led by mining and energy stocks amid rebounding commodity prices.
RTTNews | Pred 1 h 29 min
Asian Markets Track Wall Street Higher

Asian Markets Track Wall Street Higher

Asian markets are trading mostly higher on Thursday, following the broadly positive cues from Wall Street overnight, as some traders looked to pick up stocks at reduced levels following the recent sell-off. Traders also react to upbeat private US economic data and growing expectations that the US Supreme Court may reject the Trump administration's aggressive trade policy.
RTTNews | Pred 1 h 56 min
Nástroje
Ekonomický kalendár
Otváracie hodiny trhu
Úrokové sadzby
Kalendár sviatkov
Forexový trh
Forex Volatilita
Korelácia Forexu
Novinky na Forexe
Analýza forexu
COT Údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Ekonomické ukazovatele
Komunita
Komunita
Systémy
Najpopulárnejšie systémy
Stratégie
Súťaže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenzie
Brokeri
Proprietárne obchodné firmy
Služby VPS
Poskytovatelia signálu
Služby programovania EA
Partnerské programy
Služby brokera PAMM
Služby zľavového programu
Obchodné platformy
Odborní poradcovia
Kryptoburzy
Obchodné kurzy
Brokeri
Forex Spready
Ponuky Forex brokerov
Swapy Forex brokerov
Objem brokera Forexu
Propagačné akcie Forex Brokera
Tlačová Správa
Platforma
Miniaplikácie
Funkcie
API
RSS
Stock Portfolio
Affiliate Software
Rozšírené grafy
Podpora
Často kladené otázky
Pomoc
Kontaktuj nás
Nahlásiť chybu!
O
Blog
& copy; 2025 Myfxbook Ltd. Všetky práva vyhradené.
UPOZORNENIE NA VYSOKÉ RIZIKO: Obchodovanie s devízami prináša vysokú úroveň rizika, ktoré nemusí byť vhodné pre všetkých investorov. Páka vytvára ďalšie riziká a straty. Než sa rozhodnete obchodovať s devízami, dôkladne zvážte svoje investičné ciele, úroveň skúseností a toleranciu voči riziku. Môžete prísť o časť alebo všetky svoje počiatočné investície. Neinvestujte peniaze, ktoré si nemôžete dovoliť stratiť. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všetky údaje a informácie sú poskytované „tak, ako sú“. iba na informačné účely a nie je určené na obchodné účely alebo rady. Výkonnosť v minulosti neznamená výkonnosť v budúcnosti.